Home › Research › Inflammation and the immune system
Potential Benefits of Quercetin through P2X7 Modulation against Neuroinflammation in Alzheimer's Disease
Matheus Chimelo Bianchini, Francini Franscescon, Adinei Abadio Soares, Vinicius Ansolin, Kailane Paula Pretto, Marcelo Lemos Vieira da Cunha, Débora Tavares de Resende e Silva. Current Neuropharmacology, 2025-04-15
Topic: Brain proteins, microglia and lab models
Alzheimer's disease is the leading cause of dementia worldwide. It belongs to the group of neurodegenerative ailments caused by the accumulation of extracellular β-amyloid plaques (Aβ) and intracellular neurofibrillary tau tangles, which damage brain tissue. One of the mechanisms proposed involves protein neurotoxicity and neuroinflammation through the purinergic system pathway. Several endogenous nucleotides, such as Adenosine 5'-triphosphate (ATP), are involved in cell signaling. High ATP levels can cause P2X7 receptor hyper-stimulation, resulting in an exacerbated inflammatory process and in apoptosis of cells. From this perspective, searching for new therapies becomes important to assist in the patient's treatment and quality of life. As a flavonoid with several properties, including anti-inflammatory activity, Quercetin may be an alternative to alleviate the damage and symptoms caused by Alzheimer's disease. Therefore, this review aims to examine the potential of Quercetin through P2X7 modulation against neuroinflammation in Alzheimer's disease, as it affects the P2X7 receptor by direct and indirect interactions, resulting in decreased inflammation levels. Therefore, we believe that Quercetin may have significant power in modulating the P2X7 receptor, demonstrating that the purinergic system has the potential to modulate neuroinflammation and can add to the treatment, reduce disease progression, and result in better prognoses. Furthermore, technological alternatives such as Quercetin micronization might improve its delivery to target tissues.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bianchini, M. C., Franscescon, F., Soares, A. A., Ansolin, V., Pretto, K. P., da Cunha, M. L. V., et al. (2025). Potential Benefits of Quercetin through P2X7 Modulation against Neuroinflammation in Alzheimer's Disease. Current Neuropharmacology. https://doi.org/10.2174/011570159x355614250130100132
Vancouver
Bianchini MC, Franscescon F, Soares AA, Ansolin V, Pretto KP, da Cunha MLV, et al. Potential Benefits of Quercetin through P2X7 Modulation against Neuroinflammation in Alzheimer's Disease. Current Neuropharmacology. 2025. doi:10.2174/011570159x355614250130100132. PMID: 40231522.
BibTeX
@article{bianchini2025-40231522,
author = {Bianchini, Matheus Chimelo and Franscescon, Francini and Soares, Adinei Abadio and Ansolin, Vinicius and Pretto, Kailane Paula and da Cunha, Marcelo Lemos Vieira and Silva, Débora Tavares de Resende e},
title = {{Potential Benefits of Quercetin through P2X7 Modulation against Neuroinflammation in Alzheimer's Disease}},
journal = {Current Neuropharmacology},
year = {2025},
doi = {10.2174/011570159x355614250130100132},
pmid = {40231522},
url = {https://doi.org/10.2174/011570159x355614250130100132}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Therefore, we believe that Quercetin may have significant power in modulating the P2X7 receptor, demonstrating that the purinergic system has the potential to modulate neuroinflammation and can add to the treatment, reduce disease progression, and result in better prognoses.
Why it matters
This review proposes that the plant compound quercetin may reduce neuroinflammation by modulating the P2X7 receptor. It presents a hypothesis based on existing evidence rather than testing quercetin as a treatment in patients.
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Neuropharmacology) |
| Journal's citation record | 1 / 4 | Current Neuropharmacology: journal h-index 141 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Débora Tavares de Resende e Silva: h-index 10 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidade Federal da Fronteira Sul: institution h-index 102 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40231522) |
| Free to read | 2 / 2 | Free to read |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2174/011570159x355614250130100132
- PubMed: 40231522
- Original source →
- Free full text: Europe PMC (PubMed Central) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.